Abstract
Binding of a BMP to its cognate cell surface receptors is the initiating step in the BMP signaling cascade. Thus, knowing which BMP–receptor complexes form is vital for understanding the physiological activities of a particular BMP. Here, we describe a surface plasmon resonance (SPR)-based, high-throughput approach that allows fast identification and evaluation of BMP–receptor complexes. Briefly, the extracellular, BMP-binding domains of receptors are produced as human IgG1-Fc-fusion proteins. The Fc moiety enables simple capture of the Fc-receptor-fusion protein on the sensor chip, supports a highly reproducible, uniform approach of surface regeneration, and ensures full activity of the receptor moiety. BMPs are injected over the captured receptors at one concentration (approximately 60–100 nM), permitting stratification of high-affinity, medium-affinity, and low-affinity binders. Using this concentration range, equilibrium dissociation constants for high-affinity and medium-affinity binders can be estimated with good accuracy and with great precision from the single injection binding curves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, Nohe A (2011) Bone morphogenetic proteins: a critical review. Cell Signal 23(4):609–620. https://doi.org/10.1016/j.cellsig.2010.10.003
Goumans MJ, Mummery C (2000) Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice. Int J Dev Biol 44(3):253–265
Werner S, Alzheimer C (2006) Roles of activin in tissue repair, fibrosis, and inflammatory disease. Cytokine Growth Factor Rev 17(3):157–171. https://doi.org/10.1016/j.cytogfr.2006.01.001
Wakefield LM, Hill CS (2013) Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat Rev Cancer 13(5):328–341. https://doi.org/10.1038/nrc3500
Massague J (2008) TGFbeta in cancer. Cell 134(2):215–230. https://doi.org/10.1016/j.cell.2008.07.001
Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113(6):685–700
Weiss A, Attisano L (2013) The TGFbeta superfamily signaling pathway. Wiley Interdiscip Rev Dev Biol 2(1):47–63. https://doi.org/10.1002/wdev.86
Massague J (2012) TGFbeta signalling in context. Nat Rev Mol Cell Biol 13(10):616–630. https://doi.org/10.1038/nrm3434
Moustakas A, Heldin CH (2009) The regulation of TGFbeta signal transduction. Development 136(22):3699–3714. https://doi.org/10.1242/dev.030338
Olaru A, Bala C, Jaffrezic-Renault N, Aboul-Enein HY (2015) Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis. Crit Rev Anal Chem 45(2):97–105. https://doi.org/10.1080/10408347.2014.881250
Townson SA, Martinez-Hackert E, Greppi C, Lowden P, Sako D, Liu J, Ucran JA, Liharska K, Underwood KW, Seehra J, Kumar R, Grinberg AV (2012) Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex. J Biol Chem 287(33):27313–27325. https://doi.org/10.1074/jbc.M112.377960
Aykul S, Martinez-Hackert E (2016) Transforming growth factor-beta family ligands can function as antagonists by competing for type II receptor binding. J Biol Chem 291(20):10792–10804. https://doi.org/10.1074/jbc.M115.713487
Sako D, Grinberg AV, Liu J, Davies MV, Castonguay R, Maniatis S, Andreucci AJ, Pobre EG, Tomkinson KN, Monnell TE, Ucran JA, Martinez-Hackert E, Pearsall RS, Underwood KW, Seehra J, Kumar R (2010) Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J Biol Chem 285(27):21037–21048. https://doi.org/10.1074/jbc.M110.114959
Aykul S, Ni W, Mutatu W, Martinez-Hackert E (2015) Human cerberus prevents nodal-receptor binding, inhibits nodal signaling, and suppresses nodal-mediated phenotypes. PLoS One 10(1):e0114954. https://doi.org/10.1371/journal.pone.0114954
Aykul S, Martinez-Hackert E (2016) New ligand binding function of human cerberus and role of proteolytic processing in regulating ligand-receptor interactions and antagonist activity. J Mol Biol 428(3):590–602. https://doi.org/10.1016/j.jmb.2016.01.011
Aykul S, Martinez-Hackert E (2016) Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis. Anal Biochem 508:97–103. https://doi.org/10.1016/j.ab.2016.06.025
Castonguay R, Werner ED, Matthews RG, Presman E, Mulivor AW, Solban N, Sako D, Pearsall RS, Underwood KW, Seehra J, Kumar R, Grinberg AV (2011) Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 286(34):30034–30046. https://doi.org/10.1074/jbc.M111.260133
Weber D, Kotzsch A, Nickel J, Harth S, Seher A, Mueller U, Sebald W, Mueller TD (2007) A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor. BMC Struct Biol 7:6. https://doi.org/10.1186/1472-6807-7-6
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Aykul, S., Martinez-Hackert, E. (2019). High-Throughput, Biosensor-Based Approach to Examine Bone Morphogenetic Protein (BMP)–Receptor Interactions. In: Rogers, M. (eds) Bone Morphogenetic Proteins. Methods in Molecular Biology, vol 1891. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8904-1_5
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8904-1_5
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8903-4
Online ISBN: 978-1-4939-8904-1
eBook Packages: Springer Protocols